High cost dialysis and transplantation — dilemmas for nephrologists and nations by Wing, A J
The Ulster Medical Joumal, Volume 54, Supplement, pp. S62 -S69, August 1985.
High cost dialysis and transplantation
dilemmas for nephrologists and nations
A J Wing
SUMMARY
The linked successes ofdialysis and transplantation pose dilemmas for nephrol-
ogists struggling to meet the clinical need andforhealth careplanners wondering
where to find the resources required. The low rate ofacceptance ofnew patients
in the UK compares unfavourably with the service given in other countries.
Successful rationing is achieved by a sparse distribution of centres and of
specialists and operates through a low rate ofreferral ofpatients to nephrologists.
Political initiative is beginning to emerge to redress the underprovision offacilities
by setting realistic targets before regional health authorities.
INTRODUCTION: DILEMMAS POSED BY SUCCESS
It is the success of dialysis and kidney transplantation during the past 25 years
which now poses dilemmas for nephrologists and nations. Renal replacement
therapy (RRT) prolongs life for patients who would otherwise die of end-stage
renal failure (ESRF). This life is of a reasonable quality and patients have an
expectation that RRT will be offered to them if they need it.
The modern treatment of ESRF consists of complementary dialysis and trans-
plantation. Most renal units have available both haemodialysis and peritoneal
dialysis. Haemodialysis is carried out both in the hospital unit and by patients in
their own homes. Peritoneal dialysis when used for long-term therapy is usually
administered as continuous ambulatory peritoneal dialysis (CAPD). Individual
patients may experience all these methods of therapy at various times in their
careers on RRT. The treatments are thus termed 'integrated'. Reasons for choice
of one therapy at a particular time include patient preference as well as medical
and domestic considerations. Inevitably, economic factors enter into such
deliberations and it is seldom possible to take these decisions for an individual
without weighing their effect on the group of patients in a programme.
This paper presents data from the patient registry organised by the European
Dialysis and Transplant Association-European Renal Association (EDTA-ERA)
to illustrate the differences in provision of RRT in various European countries.'
Mechanisms which ration high cost medical care in the United Kingdom have
been investigated.2 Ethical dilemmas for governments which provide health care
and for doctors in this case nephrologists who dispense it are becoming
ever more painful.
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THE COST OF DIALYSIS AND TRANSPLANTATION
RRT is expensive. The price is excessive for poor nations and not without
embarrassment for the wealthier. It is a popular misconception that the cost of
treatment is the price of a kidney machine. The capital cost of a machine which
manufactures dialysis fluid and monitors the dialysis procedure is around £5,000
to £6,000. The revenue implications in terms of consumables - disposable
dialysers, blood lines, dressings and drugs - amount to a further £2,000 to
£3,000 per annum. In addition there are the overheads of the renal unit and its
staff.
Overall costs of the different methods of dialysis and of transplantation in its first
and subsequent years are given inTable1.3Successful transplantation is obviously
the 'best buy'. From this the economic importance of cadaver procurement is
evident. However, nearly all patients experience a short or long period on dialysis
while waiting for a suitable graft, and dialysis should also be provided for patients
whose grafts have failed. A graft carries greater risks for certain patients but risks
are diminishing as results improve and its lower cost will encourage doctors to
offer transplantation to a wider spectrum of patients with ESRF.
TABLE I
Costs ofvarious methods ofRRT (Mancini, 19843)
£
Hospital haemodialysis 10,650 - 12,300
Home haemodialysis 7,250 - 7,850
CAPD 6,050- 6,950
Successful transplantation:
Firstyear 5,600- 6,400
Subsequentyears 1,600- 1,850
Mean survival exceeds ten years. A clinical decision to admit a patient to an
integrated treatment programme therefore obligates approximately £;100,000 at
present-day prices. Because of good results, the stock of patients in a
programme may be expected to continue rising for many years before it reaches
a plateau. In no country has the number of patients alive on RRT yet levelled off.
It must therefore be predicted that the economic burden in terms of personnel
and plant will continue to increase.
The treatment of ESRF began in the 1960s, a period of expanding economies
when even the moon was coming within the reach of mankind. In the United
Kingdom, central funding was provided by the Department of Health and Social
Security (DHSS) to get the programme off the ground. The geographical
distribution of centres matched the major concentrations of populations and was
a fine advertisement for a nationalised organisation moving in a co-ordinated and
imaginative way to bring a new advance in therapy to the population it served.
However, health authorities have since learntthatcapital grantswithout an annual
increment to meet the revenue implications are often less than welcome.
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The two decades of RRT have witnessed increasing concern at the cost of high
technology medicine and the growing proportions of gross national product
consumed by health care. Godber has discussed the need to strike a balance in
health expenditure between therapy, prevention and support.4 He advocated
compromise to provide the most for the most and not everything for a few. The
small number of patients with ESRF whose treatment is readily costed are
beginning to be seen as consuming more than their fair share of medical
resources. Yet how fair was it that their lives should be held ransom by kidney
disease which can only be treated by continuing substitution therapy rather than
pneumonia cured with a week's antibiotics or a perforated peptic ulcer corrected
by a single operation?
The conflicting claims of preventive measures and transplant surgery are not
infrequently the cause of public debate and were the subject of an interesting
correspondence in The Times in 1979. 1 have kept this correspondence on my
files and while re-reading it recently found my attention riveted on one letter:
" * * * * is entitled to write at length about prevention being better than cure in
medicine as in other things. But I trust he will not overlook a substantial number
ofpeople forwhom prevention will come too late .... "The reason whythis letter
so caught my eye was the name of the author: unknown to me when he wrote it
five years before, he had in recent weeks become my patient and commenced
dialysis.
NATIONAL DIFFERENCES IN THE PROVISION OF RRT
The EDTA-ERA Registry has a computer file of almost 150,000 patient records
going back to the beginning of dialysis and transplantation in Europe. It is a
uniquely comprehensive record of medical endeavour. Tables 11 and III and
Figures 1 5 are derived from this data-base.
TABLE II
Numnber ofcentres and ofpatients per million population (pmp)
on 31 December 1983 in various European countries
Pop. Known Registerd patients pmp
(millions) centres Haemo- Peritoneal
pmp dialysis dialysis Graft TOTAL
Benelux* 24.2 4.5 161 14 62 237
Fed Rep Germany 61.2 4.9 221 6 31 258
France 53.4 3.9 202 17 36 255
German Dem Rep 16.8 3.1 73 1 24 98
Irish Republic 3.3 1.5 51 11 56 119
Israel 3.8 6.8 220 24 57 301
Scandinavia** 22.5 3.9 69 21 98 188
Spain 37.0 5.0 190 15 30 236
Switzerland 6.5 5.2 166 28 72 267
United Kingdom 55.9 1.1 62 23 68 153
Yugoslavia 22.1 3.4 95 1 6 103
Belgium, Luxembourg and The Netherlands.
**Denmark, Finland, Iceland, Norway and Sweden.
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Table 11 shows the number of centres providing treatment and the cumulative
stock of patients in each country, each figure being given per million of
population to facilitate comparisons. The number of centres is a constraint on
patient numbers and the low number ofpatients in the United Kingdom, only 153
patients per million population (pmp), is obviously related to the restricted
number of centres, 1.1 pmp. Average work load per UK centre is thus much
greaterthan in the average European centre indicating that British centrestend to
be larger and probably more cost-effective. The stock of patients describes the
current work load and the staff and facilities are related to this.
The opportunity for a new patient to obtain treatment is determined by the rate of
acceptance of new cases and Table III shows the rates for patients aged under
and over 65 in different countries. The low acceptance rate in the UK particularly
disadvantages patients aged more than 65.
TABLE III
Rate ofacceptance ofnewpatients ofall ages and over 65permillionpopulation
in 1983 in various European countries
New patients New patients
Country all ages >65
pmp pmp
Benelux 52 11
Fed Rep Germany 56 12
France 44 10
German Dem Rep 28 1
Irish Republic 24 1
Israel 67 13
Scandinavia 52 8
Spain 61 7
Switzerland 55 10
United Kingdom 33 3
Yugoslavia 32 2
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Fig 1. Number of patients per million population
on RRT in four large European countries
according to method of treatment.
Not only do the constraints operating
in the UK limit patient numbers, they
also have a marked effect on the
distribution of patients between
different treatment modalities (Fig 1).
Because of the limitation of hospital
stations in the UK, patients who can
only be treated by hospital haemo-
dialysis (Fig 2) are accepted with
reluctance because they might block
hospital facilities which are the
corridor to home haemodialysis,
CAPD, and transplantation. A pattern
of selection has emerged in which
patients who are capable of
independent treatment are accepted
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and those who are not are excluded. However, RRT in elderly and dependent
patients has been shown to result in a satisfactory quality of life and worthwhile
survival. Their exclusion from therapy in the UK cannot be justified on clinical
grounds and can only be attributed to valuejudgements forced on doctors bythe
economic constraints under which they work.
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Fig 2. Number of patients aged over 65 per million population on RRT in four large European
countries according to method of treatment.
Figure 3 shows how the numbers of patients have accumulated year by year on
different methods of therapy in the UK. Figure 4 compares the achievements in
Northern Ireland. The population of 1.5 million in Northern Ireland is served by
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Fig 3. Cumulative stock of patients on 31
December 1974- 1983 according to method of
treatmentinthe UK. (Figuresfor 1983incomplete).
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Fig 4. Cumulative stock of patients on 31
December 1974 - 1983 according tomethod
of treatment in Northern Ireland.
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the single unit whose 25th anniversary is celebrated by this Symposium. The
excellent results of transplantation5 have made a vital contribution here over the
years. Unlike practice in the rest of the UK, CAPD has not yet been used
extensively to help out hard-pressed hospital haemodialysis.
RATIONING OF RRT IN THE UK
All British nephrologists testify to the pressure under which their units are
operating but it seems that they very seldom have to turn away patients whom
they consider suitable for treatment and certainly never at the anticipated rate of
25 patients per unit peryear. Isthe need for treatment less in the UK? There is no
evidence that the incidence of ESRF is lower in the UK than in other European
countries. Then, where are the untreated patients? What is happening to them.6
The answer lies in the mechanism of access to specialised services under the
National Health Service. The patient cannot refer himself directly to the specialist
who he deems will help him most. Hospital specialists only see patients at the
request oftheir general practitioners. It is therefore possible that treatment rate is
controlled by the physician who first diagnoses ESRFwhen he decideswhetheror
not to refer a patient. The 'gatekeeper' could be the primary care physician but it
seems more likely that it will be the consultant in the hospital where the diagnosis
is made. Chronic renal failure requires only a biochemical test of the blood to
make the diagnosis but before that isdone it can masquerade under manyclinical
presentations since uraemia causes diverse symptoms. Moreover, approximately
one-third of all patients with ESRF have followed an insidious course and present
as acute uraemic emergencies, often requiring dialysis within a few days if not
hours. Because ofthe low ratio of renal units to population in the UK, the patient
has a four-out-of-five chance of being diagnosed in a district general hospital
without a nephrologist or a renal unit. If he is to be treated he must be referred to
another hospital, perhaps 50 miles or more distant from his home.
To test this explanation forthe lowtreatment rateofESRF in the UK we circulated
a questionnaire containing 16 brief patient histories to a random selection of
general practitioners and consultant physicians and to all nephrologists in the
UK.2 The respondents were asked whether they thought each of the cases
suitable for dialysis and/or transplantation. All the cases had complicating
medical and domestic problems mitigating against successful good quality life on
RRT. A significantly higher (p <0.001) number of the 16 cases was rejected by
both consultant physicians (7.4 ± 0.2) and general practitioners (6.9 ± 0.3) than
by nephrologists (4.7 + 0.3). Interestingly, the ranking of patients according to
suitability produced a close correspondence between the three groups ofdoctors
suggesting that factors other than specialist knowledge determined 'negative
selection'.
The same questionnaire was also sent to colleagues in Europe and North
America asking them to circulate it amongst primary care doctors and non-
nephrologists. Negative selection averaged 0.3 ofthe 16 cases in North America,
3.6 in Western Europe and 7.5 in Eastern Europe, suggesting that decisions of
British consultant physicians reflect an assessment of facilities for RRT in the UK
on a par with the health services of communist countries.
Some of the unsolicited letters received with the questionnaires were particularly
enlightening. Whereas we were told that in Europe and the USA a specialist
nephrologist would virtually always have been consulted aboutthe decisions, one
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British consultant physician wrote: ". . . . I worked at my local renal unit in a
junior capacity some years ago. I have always referred on merit and not based on
what I know to be the facilities locally but I have made the valuejudgements as to
who is meritorious myself .... the decision is mine rather than my local renal
unit's .... ".
It may be thought commendable that individual doctors can shoulder such a
responsibility. That they can do so at all probably owes much to the social
structureof our countryand thetraditional paternalismofourlearned professions.
In the face of such a system, which patients are likely to get through to the renal
unit? The young and beautiful, certainly. The articulate and aggressive, possibly.
Those whose families, parents, children and friends will take up their cause. The
request for a second opinion is a rarely exercised privilege under the NHS. Media
publicity suggests that it should be invoked more often. 7 In the meantime, a
rough and ready system of triage is at work maintaining a delicate equilibrium
between clinical need and available facilities. In shielding their patients from the
anguish of being turned down for treatment, NHS doctors are making decisions
on out-of-date criteria. It appears likely that this mechanism for rationing the
demands on high technology, high cost medicine and surgery also regulates
referral in other specialities.
IMPROVING THE SERVICE FOR PATIENTS WITH ESRF
As a physician caring for patients with ESRF and because of my involvement with
the EDTA-ERA Registry, I cannot do other than act as advocate for the cause of
RRT in the UK. Physicians in this field have taken a great deal of trouble to
catalogue their achievements and to assess the quality of life of their patients in
an objective manner. The costs of treatment can be readily identified. The
comDonents of the cost-effectiveness eauation are known. Other areas of hiah
cost care will need to collect their
own data.8 The dilemmas as to which
patients should be selected for treat-
ment and how much resource should
be allocated to each area will continue
to be debated.
At the present time it is acknowledged
that the rate of acceptance of new
patients in the UK is too low. The DHSS
is setting a target of40 new patients per
million of population 'by 1987'. The
chances of therapy for a British patient
would then be raised to the level of
those currently available in Greece and
Portugal, but would still be inferior to
those in West Germany, France, Italy
and Spain and many other small
Western European countries. The
current rate of increase in acceptance
rate seems likely to realise this target,
possibly without additional centres
being opened (Fig 5). More imaginative
is the target ofthe Secretary ofStatefor
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Fig 5. Increase in rate of acceptance of new
patients in five European countries. (1983
figures provisional).
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Health for Wales who has announced his intention to treat 50 patients pmp.
Subsidiary renal units are being opened in Wales to accomplish this and the
experiment in the Principality will be watched with great interest by the rest of
the UK.
Northern Ireland has no plans, so far as I know, to augment its single renal unit
which has made such a famous contribution over the last 25 years. Perhaps
limited facilities could be used more intensively, by the institution of an overnight
programme,9 and perhaps the addition of CAPD to the treatment options will
ease the pressures under which Dr McGeown and her staff are serving the
population of Ulster. Good luck for the years ahead!
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